Authors

Daniel Catenacci, MD, University of Chicago Medicine

Latest:

Dr. Catenacci on Navigating HER2 Testing in Gastric/GEJ Cancer

Daniel Catenacci, MD, discusses navigating HER2 testing in gastric and gastroesophageal adenocarcinoma.

Daniel Costin, MD

Latest:

Dr. Costin on Initial Considerations in Early-Stage Lung Cancer

Dan Costin, MD, discusses initial considerations in early-stage lung cancer.

Daniel DeRemer

Latest:

Patient Education on Oral Chemotherapy

Daniel DeRemer, PharmD, assistant director of Clinical Therapeutics and Incubator, discusses patient education on oral chemotherapy.

Daniel Dosoretz MD

Latest:

Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter Validation

Rapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.

Daniel E. Dosoretz, MD

Latest:

Changes in Prostate Cancer Presentation for Radiation Oncology Care

USPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.

Daniel Eidelberg Spratt, MD

Latest:

Advances in ADT Personalization and Molecular Imaging Shape Updated NCCN Prostate Cancer Recommendations: With Daniel Spratt, MD

Daniel Spratt, MD, discusses key updates to the National Comprehensive Cancer Network Guidelines for prostate cancer.

Daniel F. Hayes, MD

Latest:

Dr. Hayes on the Future of Biomarkers for Breast Cancer

Daniel F. Hayes, MD, professor at the University of Michigan Comprehensive Cancer Center, discusses the future of biomarkers for patients with breast cancer.

Daniel G. Coit, MD

Latest:

Dr. Coit on the Evolving Role of Surgery in Patients With Melanoma

Daniel G. Coit, MD, FACS, surgical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of surgery in treating patients with melanoma.

Daniel G. Haller, MD, FACP, FRCP, Perelman School of Medicine

Daniel G. Haller, MD,FACP,FRCP, University of Pennsylvania

Daniel G. Haller, MD, University of Pennsylvania

Daniel G. Stover, MD

Latest:

Neoadjuvant and Adjuvant Chemotherapy Considerations for Triple-Negative Breast Cancer

Growing attempts to develop biomarkers to guide therapy within triple-negative breast cancer may lead to more effective regimens or to novel therapeutic targets.

Daniel George, MD

Latest:

Dr George on Other Potential Roles for Radioligand Therapy in Prostate Cancer

Daniel J. George, MD, discusses the potential use of lutetium-177 earlier in the treatment paradigm for metastatic castration-resistant prostate cancer.

Daniel George, MD, Duke Cancer Institute

Daniel H. Ahn, DO

Latest:

Dr. Ahn on the Evolution of First-line Treatment Options in HCC

Daniel H. Ahn, DO, discusses the evolution of first-line treatments in advanced hepatocellular carcinoma.

Daniel H. Ahn, MD

Latest:

Dr. Ahn on Link Between Tumor Somatic Variants and Chemo Resistance in Biliary Tract Cancer

Daniel H. Ahn, MD, assistant professor of Medicine, Mayo Clinic, discusses a next-generation sequencing survey of biliary track cancer to reveal the association between tumor somatic variants and chemotherapy resistance.

Daniel H. Fowler, MD

Latest:

Dr. Fowler on the Mechanism of Action of T-rapa Cells

Daniel H. Fowler, MD, senior investigator, Center for Cancer Research, National Cancer Institute, describes the mechanism of action of T-rapa cells.

Daniel H. Galmarini

Latest:

Daniel H. Galmarini Provides an Overview of Adaptive Radiotherapy

Daniel H. Galmarini, Chief Technology Officer/Director, Physics and Engineering, 21st Century Oncology, provides an overview of adaptive radiotherapy.

Daniel Haraf, MD

Latest:

Dr. Haraf on Induction Chemotherapy With Radiation For Advanced Head and Neck Cancer

Daniel Heng,